<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237610</url>
  </required_header>
  <id_info>
    <org_study_id>38RC18.171</org_study_id>
    <secondary_id>2018-A01962-53</secondary_id>
    <nct_id>NCT04237610</nct_id>
  </id_info>
  <brief_title>Reward and Punishment Sensitivity in Bipolar Disorders</brief_title>
  <acronym>Recodec-BP</acronym>
  <official_title>Reward and Punishment Sensitivity in Bipolar Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bipolar disorder (BD) represents a chronic mood disorder and one of the leading causes of
      disability worldwide. Complexity of its clinical presentations leads to delayed diagnosis and
      difficult management in routine clinical settings. Whereas distinguishing BD-I and BD-II main
      subtypes has a significant relevance for treatment strategy and for outcome, there are
      currently no clinical determinants of the BD subtype which could be used as early diagnostic
      predictors.

        -  While neurobiological specificity of each BD subtype is still controversial, available
           evidence suggest different dopaminergic abnormalities in each subtype. Dopaminergic
           function is involved in decision making and reward processing which may represent useful
           BD subtype markers.

        -  This study aims at assessing decision making during appetitive and punitive
           reinforcement learning in patients with BD I and BD II subtypes compared to healthy
           controls
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response performance in reward and loss trials</measure>
    <time_frame>one day visit</time_frame>
    <description>percentage of correct responses in the probabilistic learning task</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Bipolar disorder type I</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar disorder type II</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>behavioral assessment</intervention_name>
    <description>Probabilistic learning task</description>
    <arm_group_label>Bipolar disorder type I</arm_group_label>
    <arm_group_label>Bipolar disorder type II</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bipolar disorder, type I and II, in a inter critical phase (euthymic period
        defined by the mood scales scores mentioned in the inclusion criteria)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bipolar disorder (BD) type I or II, according to DSM (Diagnostic and Statistical
             Manual)-5 criteria

          -  Montgomery and Asberg Depression Rating Scale (MADRS) score &lt; 15

          -  Young Mania Rating Scale (YMRS) score &lt; 12

        Exclusion Criteria:

          -  other main diagnosis than bipolar disorder

          -  other medical condition leading to cognitive deterioration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mircea POLOSAN, MD, PhD</last_name>
    <phone>0033476765414</phone>
    <email>mpolosan@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnaud POUCHON, MD</last_name>
    <email>apouchon@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Polosan Mircea</last_name>
      <phone>0033476765414</phone>
      <email>mpolosan@chu-grenoble.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>reinforcement learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

